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Synthetic biology is an investigative and constructive means of understanding the
complexities of biology. Substantial progress in the fields has resulted in the creation of
synthetic gene circuits, which when uploaded into the appropriate nanoliposomal vehicle,
can be used for a tunable response in a cell. These tunable elements can be applied to
treat diseased condition for a transition to a healthy state. Though in its nascent stage
of development synthetic biology is beginning to use its constructs to bring engineering
approaches into biomedicine for treatment of infectious disease leishmaniasis.
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In the twentieth century, Feynman’s “There is plenty of room at the bottom” lecture for the meeting
of American Physical Society at Caltech (1959) opened a firework of intellectual concepts to a wide
range of themes within physics and wherever physics was involved. This lecture laid the foundation
of creating nano sized entities that could be useful for human welfare. Alongside, people in the
creative industry were coming up with crazy stories that brought up the Hollywood science fiction
movie Fantastic Voyage in 1966 with illustrations of nanorobots with medical abilities. These could
excavate plaque in clogged blood vessels, locate pathogens, and inject materials into the red blood
cells. These conveyed that nanomedicine could be the “next” big step to cure diseases with precision
(1). But it was only with the invention of scanning tunneling microscope in 1981; almost 15 years of
Feynman’s Caltech lecture that nanotechnology emerged as a major research discipline. Since then
nano sizedmaterials havemade their impact in almost all facets of human life; of particular mention
is its contribution to medicine. Man-made nanoscale systems match the scale of the physiological
working levels in biology and therefore have great relevance to its application in the field. A variety
of nanoscale materials are being used in medical and clinical research as detectors, targeted drug
delivery vehicles, in drug screening, imaging, and diagnosis (2). With advances in nanotechnology,
today’s nanomedicine come packed in surface modified nanocarriers having immense therapeutic
potential due to their targeted action and biocompatibility; and are available in the market (3)
(Table 1A). Also previously inaccessible areas of the body can be made accessible by propelling
the nanodevices by a variety of fuel and fuel free driven technologies to deliver therapeutic and
diagnostic agents (4) (Table 1B).
Nanotechnology to medicine is becoming more promising as biocompatible materials like
proteins, RNA, and DNA (Table 1C) are being molded into nano cargoes with targeting scaf-
folds for targeted delivery systems (11–18). These natural polymers have the tendency to self-
assemble into versatile nanostructures using the information encodedwithin their defined sequence.
Abbreviations: caNanoLab, cancer nanotechnology laboratory; ECM, extra cellular matrix; ISA-TAB-Nano, investigation
study assay tab-delimited format; ODN, oligo-deoxynucleotides; PAMAM, poly (amidoamine); PAMP, pathogen associated
molecular patterns; PEG, polyethylene glycol; QSAR, quantitative structure–activity relationship; SNAPL, stable nucleic acid
lipid particle; STV, streptavidin; TLR, toll like receptors.
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TABLE 1 | (A) Nanomedicines; (B) Propelling systems applied to nanodevices; (C) Biomolecules as nanostructures in therapeutics.
(A) NANOMEDICINES AVAILABLE IN THE MARKET AND THEIR INDICATIONS
Drug Nano carrier Application Brand name
Paclitaxel Albumin-bound nanoparticles Metastatic breast cancer Abraxane®
Doxorubicin Liposomes Metastatic breast cancer Myocet®
Doxorubicin PEGylated liposomes Metastatic breast and ovarian cancer; Kaposi sarcoma Caelyx®
Daunorubicin Liposome Kaposi sarcoma DaunoXome®
Amphotericin B Liposome Fungal infections and cutaneous leishmaniasis AmBisome®
Monoclonal sheep antibody PAMAM dendrimers Cardiac marker diagnostic Stratus®
(B) PROPELLING SYSTEMS
Propulsion mode Nano carrier Application
Catalytic Multilayer microtubes (5) Immuno-micromachine-based approach for in vitro detection circulating
tumor cells without sample preprocessing (6)
Magnetic Tumbling nanowires (7) Magnetic resonance guided microcarrier for liver chemoembilization (8)
Ultrasound Mutilayer microtubes (9) Acoustically active microbubbles for effective therapies in primary central
nervous system lymphoma (10)
(C) BIOMOLECULES AS NANOSTRUCTURES IN THERAPEUTICS
Biomolecule Application
Proteins Self assembly nanopeptide vaccines to display B-cell epitope from the malaria parasite Plasmodium berghei circumsporozoite
protein (20)
RNA Transferrin-tagged, cyclodextrin-based polymeric nanoparticles-CALAA-01, contains siRNA that targets the M2 subunit of
ribonucleotide reductase for cancer treatment (21)
HIVgp120: tat-rev siRNA chimera, a 16-nt dsRNA used as the scaffold to link the gp120 aptamer; decreases infection by blocking
gp120 and prevents replication by silencing tat-rev (22)
DNA Cancer-fighting DNA nanorobots that target specific cells for repair (23)
Of all these DNA seems to be superior as it has the struc-
tural and functional information encoded within it and a variety
of DNA manipulating enzymes provide the much needed tool
box required to design a myriad of DNA nanostructures (16).
DNA via controlled assembly can be nano-engineered to one-
dimensional (1D), two-dimensional, and 3D DNA nanostruc-
tures. DNA hybridization to short “stapler” DNA is a versatile
method to construct DNA origami nanostructures (18). Proteins
and RNA are genetically encoded into DNA sequence and there-
fore DNA sequences encoded with desired nano functionality can
be regarded the “one in all” biocompatible material for expressing
nanostructure within a cellular chassis. It can be regarded as an
aspect of synthetic biology, as using defined DNA sequences,
hybrid (protein–RNA–DNA) nanostructures can be designed and
fabricated that do not exist in nature; idealizing with the main-
frame concept of synthetic biology. This will not only add to the
wide range of functionalizing the nanostructure but alsowill aid in
the multistage nanoassembly systems (19). Thus, we can say that
DNA has come a long way from just being an entity to be studied
in genetics to a multimodal nanomachine with wide applications
in bionanomedicine.
Bioinformatics Approaches Applied
to BioNanotechnology
Post Genomics Era, Bioinformatics has taken the center stage in
storing, managing, visualizing, and retrieval of loads of data that
can be systematically dealt for understanding the complexities
in biology. Similarly, the information generated in nanotechnol-
ogy should be catered to by developing new bioinformatics and
computational tools that may be critical in designing, modeling,
simulation, and visualization of bionanosystems that may arise
with amalgamation of synthetic biology and nanotechnology. As
of now, nanotechnology is relatively new in biology and the data
that comes from experiments and modeling studies is scattered.
It is only recently that efforts like the Investigation Study Assay
(ISA) tab-delimited (TAB) format (ISA-TAB-Nano) (24), Cancer
Nanotechnology Laboratory (caNanoLab) (25) are being directed
to build databases for nanotechnology derived data. Curation of
the data in nanotechnology databases is important as experimen-
tal conditions to obtain the nanomaterial and its application can
affect the actual data measurement. Nanomaterial registry (26)
has developed a method for combinatorial analysis and cura-
tion of these datasets for characterized nanomaterials. Similarly,
tools for visualization, molecular modeling, docking, QSAR, and
Designing Biomolecular nanostructures are available (27).
For synthetic biology assisted nanotechnology, the major
advantage of an advanced computational tool will be aiding and
conceptualizing novel nanodesign with the option of exploring
many structural options and their stability statistical analysis (28,
29). The raw sequences required for nanostructure design can be
culled from the many databases available in the public domain
like the GenBank, EMBL, UniProt, RNACentral, etc. These raw
sequences can be further modified as per the demands of the
structural determinants of the conceptualized bionanostructure.
Further statistical analysis of these predicted structure helps in
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validating their stability, robustness, and evolvability. Many state
of the art mathematical packages are available likeMATLAB® and
Bioconductor that can perform various statistical analyses on the
given dataset.
Synthetic-DNA nanotechnology must be applied to infec-
tious disease like leishmaniasis. Leishmaniasis is one of the
most neglected tropical diseases of the world, killing almost
20,000–300,000 people in the developing countries. Many drugs
have been made and are still being discovered, but the proto-
zoan re-emerges showing drug resistance to the effective medi-
cations. Nanotechnology has just managed to show its promise
in developing a liposomal formulation called amphotericin B for
leishmaniasis, which is available in the market, but has serious
side effects and is not cost effective in developing countries (30).
Initial, nanodelivery systems for delivering chemotherapeutics
were nanodisks impregnanted with amphotericin B, polymeric-
nanoparticle loadedwith pentamidine, primaquine, and niosomes
(31), which still need validation at the clinical level. There is
an urgent need to take up assignments to use effective nan-
otechnology devices in combating this infectious disease. DNA
nanostructures have shown promise in treating cancer and many
of them very well could come into clinical trials in the near
future. But a lot needs to be done as far as infectious diseases
are concerned. DNA nanotechnology and its potentials can be
tapped in infectious disease for immunostimulation and vaccine
preparation.
Nanotechnology for Leishmaniasis
Leishmania are susceptible to complement-mediated lysis during
the promastigote stage of their life cycle. This form of the parasite
is found immediately after injection into the host’s blood stream
by a sandfly vector. These parasites can coat themselves with C3b
complement that act as opsonins to gain entry into macrophages
where they can survive intracellular killing. These brief window
periods of complement susceptibility could be exploited to kill
parasites with aptamers by coupling to complement-mediated
lysis (32). Aptamers can be linked to DNA or proteins that con-
fer polyvalent functionalities, one being cell internalizing capa-
bility that only targets a particular cell population and deliver
their therapeutic cargos specifically into the cell, in leishmaniasis
the promastigotes, this may enhanced therapeutic efficacy and
reduce cellular toxicity. Also, DNA nanoscaffolding of aptamers
may make them resistant to serum nucleases and impart lower
immunogenicity.
Macrophage M1 to M2 differentiation is the bottleneck for
a proinflammatory response in many of the infectious disease.
In leishmaniasis too, since the protozoan resides within the
macrophages, it blocks its transformation to M2 type and silences
the immune alarming system for an inflammatory response
deciding the pathogenesis in disease outcome. Self-assembled
nanostructures with that extracellular matrix (ECM) mimicking
capability may also display biological signals together, which
can help modify and instruct cell behavior. Structurally, pro-
grammable nanostructures can also modify signaling compo-
nents and DNA nanostructures as artificial scaffolds can be used
to control cell behavior. If these DNA nanostructures can be
coassembled with peptides having biological epitopes for cell
receptors that can act as signal for cell differentiation (33). Such
co-assemblies investigation formed could be capable of guiding
the differentiation of M1 to M2 macrophages.
The leishmanial parasite PAMPS mainly the LPGs are recog-
nized by TLR2 and TLR4, which initiates an initial but a very
short time spanning TLR-mediated inflammatory response. But
using the many survival strategies the parasite affects the TLR
signaling and subverts the inflammatory response. The endo-
somal TLRs can come to the rescue, if they are activated with
appropriate signal for disease resolving response. CpG nanostruc-
tures directed to the endosomes can be utilized for the activation
of innate immune response. The endosomal TLR3, TLR7/8, or
TLR9 recognizes exogenous or endogenous RNA/DNA in endo-
somal vesicles. Bacterial and viral DNAs harbor CpG motifs
with much higher frequency compared with mammalian DNA
and have the capability to activate the endosomal TLR signaling
(34). The activated TLR9 in macrophages can then secrete proin-
flammatory cytokines and type I. Soluble DNA nanostructures
can be used for the targeted delivery of CpG DNA to TLR9-
positive cells targeted to the macrophages harboring the leishma-
nial parasites.
Leishmania also has the capability to inhibit apoptosis of
the resident macrophages. Apoptosis can be induced in the
macrophages by using the biomimetic material platform com-
posed of self-assembling hybrid nanoconjugates as a therapeutic
system. Apoptosis is induced by clustering of CD20 within lipid
rafts. If these CD20-bound antibodies are hyper-cross-linked by
Fc receptor (FcR) on macrophages they can be made to undergo
apoptosis. These are termed as “drug-free macromolecular ther-
apeutics” due to the absence of low-molecular-weight drugs that
often show side effects (35). In this way, apoptosis induction could
be made direct and specific toward the innate immune response
for intracellular killing of the leishmanial parasite.
The leishmanial parasite is known for its ability to modu-
late the innate immune signaling for its safe intracellular sur-
vival. DNA–protein nanoscaffolds can be used for modulators
of immune signaling with in the macrophages. Earlier work
have used RNA as scaffolding device within bacterial cells with
capabilities for increased H2 production by varying the relative
geometries of the enzymes with in the cell (36). Through rational
design, both DNA and RNA can be used to create 1D, 2D, and
3D structures, allowing stable and rigid arrangements of enzymes
for favorable substrate channeling (37). Similarly, in leishmaniasis,
the innate immune signaling can be channelized for a proin-
flammatory response by orienting the signaling molecules using
DNA–RNA scaffolding machinery.
Vaccine development in leishmaniasis is another major
area where DNA nanotechnology may have an important
contribution. Till date, many efforts have been undertaken to
develop a successful vaccine, but realizing them into the clinics
has been a bottle neck. Whole cell killed, attenuated, subunit
vaccines have been developed in the past. Liposomal soluble
Leishmania antigen incorporated CpG has also been tested
in mouse model of cutaneous leishmaniasis, and generated
significant levels of protection. Recombinant proteins using
virus as a delivery vehicles have also been tested as vaccines in
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FIGURE 1 | Programmable synthetic constructs can be used to
assemble nanostructures within living cells in a controlled fashion for
leishmanicidal effects; (A) Raw sequence data of proteins, DNA, and RNA
can be retrieved from databases; (B) Raw sequence data analysis for selection
of a good sequence for nanostructure design followed by designing, modeling,
simulation, and visualization of bionanosystems; (C) Computational analysis of
the nanostructures for stability, robustness, and evolvability; (D) Generating
sequence for tailor made nano-synthetic constructs; (E) Selection of a suitable
chassis microorganism for uploading the synthetic construct; (F) Optimum
chassis uploaded with the construct for the synthesis of combinatorial
nanostructures; (G) Application of the nanostructures in the form of vaccines,
aptamers, immune modulators to leishmanial parasite for a leishmanicidal effect.
preclinical studies (38). Recent efforts are being made to assemble
multiple adjuvant elements on a DNA nanostructure, increasing
their immunostimulation capacity, highlighting the potential
of DNA nanostructures to serve as new platforms for vaccine
construction. Tetrahedral DNA nanostructure has been used
as scaffold to assemble a model antigen, streptavidin (STV),
and a representative adjuvant, CpG oligo-deoxynucleotides
(ODN), into a synthetic vaccine complex, which elicits antibody
response against the model antigen, STV. Programmable DNA
nanostructures provide an excellent platform for construction of
vaccines with multivalency and three-dimensional configuration.
The three-dimensional arrangement of each of the immunogenic
components can be readily controlled through the rational design
of the scaffold sequences (39). Strong antigenic proteins from
leishmanial parasite can be picked up for conjugation with DNA
nanostructures for vaccine development (40).
Taken together, understanding the parasite–host interaction at
the systems level and picking up the nuances in the interaction
network may aid synthetic device construction. A combinatorial
treatment strategy, with available drugs and novel nanostructures,
may be designed rationally for the treatment of leishmaniasis.
Such strategies may help overcome drug resistance and act as sup-
portive mechanism to block the functional redundancies serving
as an escape route for parasite survival (Figure 1).
Challenges: Computation in
Nano-Synthetic Biology for Leishmaniasis
Since the first genome of Leishmania species was released in
2005, four more species have been sequenced (39) and databases
like GeneDB and LeishCyc are available, which store data per-
taining to the genome and metabolic pathways in Leishmania.
Nanotechnology being applied to treat leishmaniasis is a relatively
new area of research and a lot still needs to be done to set up
merge the available datasets with new data that will arise when
nanotechnology will be applied to various aspects of the leish-
manial disease. Due to lack of information, the major research
challenges are
 Finding new reference nanomaterials using proteins, RNA,
and DNA against the leishmanial parasite
 Improved characterization of these nanomaterial
 Standardizing the experimental setupwith reproducible sen-
sitivity and accuracy
 Quantify and negate any error in protocols used to produce
the data.
Nanotechnology when applied to leishmaniasis may raise
numerous challenges due to the complexity associated with the
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life cycle of the parasite, its interaction with the host, its genome
annotation are still not delineated. Moreover, significant invest-
ment in informatics is required to accelerate current research
in understanding such a complex protozoan disease. Though
Leishmania post-genomic research projects, have transformed
the way the parasite is treated, for nanotechnological appli-
cation, computational models, and algorithm for simulations
of predicted annotated genome of Leishmania, needs a new
approach.
As we move toward understanding the complexities associated
in a diseased condition, better are the chances of discovering novel
concepts and targets for drug delivery and treatment. We envis-
age that nano-synthetic biology might revolutionize the current
biomedical science and the treatment technology in futuremaking
the illustrations of the Fantastic Voyage a reality.
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